IFNM, Institut Farmaseutikal & Nutraseutikal Malaysia (2017) A Study on the Potential of Active Constituent from Senna spectabilis in Treating Leishmania major Infection. IPHARM Newsletter, 1 (1).
|
PDF
- Published Version
Available under License Creative Commons Attribution. Download (714kB) | Preview |
Abstract
Leishmaniasis affects millions of people each year. It consists of a group of tropical infections that are effecting human populations in mainly low-income countries. Visceral Leishmaniasis (VL) and Cutaneous Leishmaniasis (CL) are the main forms of Leishmaniasis which cause mortality, chronic disability and poverty. Leishmanasis is among three of most neglected diseases in the world, together with Human African Trypanosomiasis (HAT) and Chagas’ disease. These diseases are termed as neglected diseases because they are receiving very limited press attention as well as research funding as compared to HIV/AIDS, tuberculosis and malaria. In 2003, Drugs for Neglected Diseases Initiative (DNDi) which is a non-profit drug R&D agency focusing on developing new treatments for neglected diseases was established
Item Type: | Article |
---|---|
Subjects: | R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
Divisions: | Institut Farmaseutikal & Nutraseutikal Malaysia (Malaysian Institute of Pharmaceuticals & Nutraceuticals > IPHARM Newsletter |
Depositing User: | Administrator Automasi |
Date Deposited: | 11 Sep 2017 09:59 |
Last Modified: | 11 Sep 2017 09:59 |
URI: | http://eprints.usm.my/id/eprint/36440 |
Actions (login required)
View Item |